Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Porter

Showing results (531-540 of 632) with videos related to

Pageof 64
Sort By:
Msphere|September 24, 2020
Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53GRobert W Frenck, Michelle Dickey, Akamol E Suvarnapunya, et al.
Microorganisms|October 28, 2023
Efficacy of an Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity ScoreNicole Maier, Shannon L Grahek, Jane Halpern, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Genomics|April 1, 1997
Linkage mapping in 29 Bardet-Biedl syndrome families confirms loci in chromosomal regions 11q13, 15q22.3-q23, and 16q21E A Bruford, R Riise, P W Teague, et al.
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
SARS-CoV-2 Viral Load in Saliva Rises Gradually and to Moderate Levels in Some HumansAlexander Winnett, Matthew M Cooper, Natasha Shelby, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
Infection and Immunity|December 20, 2012
The polysaccharide capsule of Campylobacter jejuni modulates the host immune responseAlexander C Maue, Krystle L Mohawk, David K Giles, et al.
Microorganisms|April 27, 2024
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic <i>E. coli</i> Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701)Kawsar R Talaat, Chad K Porter, Subhra Chakraborty, et al.
Vaccine|August 22, 2021
Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coliTida Lee, Ramiro L Gutiérrez, Milton Maciel, et al.
The Journal of Infectious Diseases|March 22, 2019
Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection ModelStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Pageof 64

Showing results (531-540 of 632) with videos related to

Sort By:
Pageof 64
Msphere|September 24, 2020
Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53GRobert W Frenck, Michelle Dickey, Akamol E Suvarnapunya, et al.
Microorganisms|October 28, 2023
Efficacy of an Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity ScoreNicole Maier, Shannon L Grahek, Jane Halpern, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Genomics|April 1, 1997
Linkage mapping in 29 Bardet-Biedl syndrome families confirms loci in chromosomal regions 11q13, 15q22.3-q23, and 16q21E A Bruford, R Riise, P W Teague, et al.
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
SARS-CoV-2 Viral Load in Saliva Rises Gradually and to Moderate Levels in Some HumansAlexander Winnett, Matthew M Cooper, Natasha Shelby, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
Infection and Immunity|December 20, 2012
The polysaccharide capsule of Campylobacter jejuni modulates the host immune responseAlexander C Maue, Krystle L Mohawk, David K Giles, et al.
Microorganisms|April 27, 2024
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic <i>E. coli</i> Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701)Kawsar R Talaat, Chad K Porter, Subhra Chakraborty, et al.
Vaccine|August 22, 2021
Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coliTida Lee, Ramiro L Gutiérrez, Milton Maciel, et al.
The Journal of Infectious Diseases|March 22, 2019
Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection ModelStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Pageof 64